Three Healthcare Related Stocks Under Focus -FUM, POLX, AGL

About Futura Medical PLC

Futura Medical Plc (FUM) is based in the United Kingdom and develops products for relieving pain and sexual wellness. The Company focuses on Research & Development of medical devices and drugs along with their commercialisation. The science of absorption of medicine or drug through a sticky patch by application on the external body, typically skin is known as Transdermal delivery. The company has developed this technology which makes the skin to absorb active molecules known as DermaSys®; focused on sexual wellness and pain relief. The company has popular products such as Zanfil (gel used by patients suffering from ED) and TPR100 (pain reliever).

FUM-Recent developments

The company decided to explore the application of DermaSys® (Futura’s advanced proprietary transdermal drug delivery technology), and therefore the company collaborated (through a Joint Venture) with CBDerma Technology Limited for delivery of Cannabidiol. The intellectual property will be owned by both the companies together. CBDerma Technology has expertise in therapeutic use of Cannabis and derived products. Cannabidiol is also a derivative of Cannabis plant. The company expects an initial investment of US$ 1 million for the development and optimisation of new formulation.

FUM-Financial highlights for H1 FY19

The company’s research and development costs were recorded at £4.74 million for period of six months ended 30th June 2019 as against £1.65 million for the same duration ended 30th June 2018.The additional £3 million costs are associated with FM57 Phase 3 study project which shall yield positive results for the company in December 2019.

The company’s administrative costs were recorded at £0.53 million for the six months ended 30th June 2019 as against £0.86 million for the same duration ended 30 June 2018. The company aims to keep lesser costs and focuses on cash resources with respect to the R&D programme.

The company had cash balances of £5.63 million by the end of the period along with R&D tax credit refund of £1.36 million received post period. Assuming the results of FM57 study are positive, the company intends to commence and complete FM59 study during 2020 but the group believes the cash balances to be insufficient. Therefore, the company is exploring several funding options and has high hopes for successful completion of FM57 trial. The company enjoyed a tax credit of £0.8 million in H1 FY19 as against £0.6 million in FY18. MED2005 is into late stage clinical development and has the potential to become an inflection point for the company going forward. The company is very excited about launching their highly differentiated products with respect to ED that can address those patients who are not getting cured by available treatments. Furthermore, the company is very prudent in leveraging DermaSys® technology and products while envisioning the future.

FUM-Share price performance

Daily Chart as at 11-September-19, before the market closed (Source: Thomson Reuters)

On 11th September 2019, at 01:24 PM GMT while writing, FUM shares were trading at GBX 38.42 per share; which were down by 9.6 per cent as compared to the closing price level of the previous day. The company’s M-cap (market capitalisation) was recorded at £86.98 million at the time of writing.

The stock’s traded volume was hovering around 2,585,321 at the time of writing before the market close. The stock’s 5-day average traded volume was 375,339.80; 30 days average traded volume- 460,521.97 and 90 days average traded volume – 948,887.00. The company’s stock is much more volatile in comparison with the index considered as the benchmark as the beta of the company’s stock was recorded at 3.33.

The shares of the company have delivered a positive return of 82.80 per cent in the last quarter. The company’s stock rocketed by 591.06 per cent from start of the year till date. The company’s stock has generated a positive return of 65.99 per cent in the prior one year. 

About Polarean Imaging PLC

Polarean Imaging Plc (POLX) is a medical imaging technology company which strives to research, develop and commercialize hyperpolarization systems for biomedical imaging research. The company manufactures high-performance MRI radiofrequency (RF) coils for imaging Xenon gas in the MRI system. Polarean Imaging’s products find application in the study, diagnosis and monitoring of various diseases, including chronic obstructive pulmonary disease (COPD), cystic fibrosis, asthma, stent placement, and radiotherapy.

 

POLX-Recent News

Amphion Innovations Plc, the partner company of Polarean Imaging Plc had a loan facility which was offset by selling 1,150,000 shares of Polarean Imaging Plc for partial repayment of loan facility. Post this transaction, Amphion holds 17,122,523 shares (of Polarean), which amounts to 14.96 per cent of the total share capital of the company. The company has successfully installed and handed over its latest polariser system (9820 Xenon) at the SickKids hospital in Toronto.

POLX-Financial results FY18

The company’s revenue was higher than expected, stood at US$2,439,139 in FY18 as against US$1,237,163 in FY17. The company’s gross profit was recorded at US$1,805,676 in FY18 as against US$939,948 in FY17. The company’s selling and distribution expenses surged to US$31,766 in FY18 as against US$28,752 in FY 17. The company’s total administrative expenses rose to US$7,072,464 in FY18 as against US$4,863,842 in FY17. The company’s finance income rose to US$184 in FY18 as against US$129 in FY17. The company had cash and cash equivalents of US$875,601 in FY18 as against US$960,217 in FY17. The company’s borrowings were down to US$5,213 in FY18 as against US$1,104,723 in FY17. The company was able to forge new agreement with Duke University.

POLX-Share price performance

Daily Chart as at 11-September-19, before the market closed (Source: Thomson Reuters)

On 11th September 2019, at 01:31 PM GMT while writing, POLX shares were trading at GBX 20.55 per share; which were up by 0.24 per cent as compared to the closing price level of the previous day. The company’s M-cap (market capitalisation) was recorded at £23.46 million at the time of writing.

The stock’s traded volume was hovering around 276,330 at the time of writing before the market close. The stock’s 5-day average traded volume was 442,650.60; 30 days average traded volume- 418,274.37 and 90 days average traded volume – 250,785.13. The company’s stock was much less volatile in comparison with the index considered as the benchmark as the beta (2Y weekly) of the company’s stock was recorded at 0.17.

The shares of the company have delivered a positive return of 28.13 per cent in the last quarter. The company’s stock rocketed by 32.26 per cent from start of the year till date. The company’s stock has generated a positive return of 35.31 per cent in the prior one year. 

 

About Angle PLC

ANGLE PLC (AGL) is a Pharmaceuticals & Biotechnology company primarily involved in Commercialization of Parsortix cell separation system. Being a diagnostic company, it offers products that will help in foetal health and cancer diagnostics. The company’s Parsortix cell separation system, with the use of microfluidic technology capture and circulate CTCs (circulating tumour cells) from the blood.  The company’s liquid biopsy (blood test) is used to detect and investigate mutations in the cancer to provide customized cancer care to patients.

 

AGL-Recent News

The Barts Cancer Institute- Queen Mary University of London has published some amazing results of new study undertaken which is far better than modern technologies in assessment and detection of prostrate cancer. This study utilises ANGLE’s Parsortix® system. This latest new work was a result of previous studies with the Parsortix® system in prostate cancer assessment in later stages.

AGL- Financial performance for FY19

The company’s revenue and grant income were recorded at £0.9 million in FY19 as against £0.7 million in FY18. The company did planned investments during the period; the company’s loss for the year was recorded at £8.9 million as against loss of £7.5 million in FY18. The company had cash balances of £11.0 million as on 30th April 2019 as against £7.6 million (as on 30th April 2018). The company was able to manage a fundraising of £18.0 million.

 

AGL-Share price performance

Daily Chart as at 11-September-19, before the market closed (Source: Thomson Reuters)

On 11th September 2019, at 01:35 PM GMT while writing, AGL shares were trading at GBX 75 per share; which were up by 8.69 per cent as compared to the closing price level of the previous day. The company’s M-cap (market capitalisation) was recorded at £119.19 million at the time of writing.

The stock’s traded volume was hovering around 248,012 at the time of writing before the market close. The stock’s 5-day average traded volume was 156,343.00; 30 days average traded volume- 318,582.70 and 90 days average traded volume – 268,347.01. The company’s stock was much less volatile in comparison with the index considered as the benchmark as the beta (2Y weekly) of the company’s stock was recorded at 0.17.

Facebook Comments